NewAmsterdam Pharma (NASDAQ: NAMS ) is a biotech company with one lead asset, namely obicetrapib which the company aims to develop for a number of indications related to cardiovascular risk. obicetrapib is a potentially best-in-class second-generation CETP inhibitor. It aims atI am a long-term investor focused on growth markets, AI and biotech opportunities in my more volatile portfolio. I try to look for undervalued and under-the-radar stocks with serious potential and good scientific or other background. ...